Review explores toxin-derived peptides showing anticancer potential in various tumors, suggesting innovative therapies.
Cancer, a longstanding global challenge, remains a leading cause of death, prompting an urgent search for effective treatments. Conventional therapies, while prevalent, often cause adverse effects due to their lack of specificity. This review explores an innovative approach, focusing on animal toxins as a rich source of bioactive compounds which have demonstrated efficacy against cancer cells. Peptides from various species, including scorpions, snakes, bees, spiders, and frogs, show promising antiproliferative and cytotoxic effects. Emphasizing the most prevalent types of cancer, this review outlines the discovery and development stages of potential anticancer drugs derived from toxin peptides. The comprehensive overview includes in vitro and in vivo assessments of their anticancer activity and toxicity. This pioneering exploration extends to different tumors, offering valuable insights into mechanisms of action and potential therapeutic applications. The findings highlight a paradigm shift in cancer research, showcasing the potential of toxin-derived compounds for developing targeted and efficient cancer therapies with reduced side effects.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: